{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:29:29Z","timestamp":1791512969506,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with non-small cell lung cancer (NSCLC), 10%-40% will eventually develop brain metastases. We present the clinicopathologic, genomic, and biomarker landscape of a large cohort of NSCLC brain metastases (NSCLC-BM) samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 3035 NSCLC-BM tested with comprehensive genomic profiling (CGP) during routine clinical care. In addition, we compared the NSCLC-BM to a separate cohort of 7277 primary NSCLC (pNSCLC) specimens. Finally, we present data on 67 paired patients with NSCLC-BM and pNSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comprehensive genomic profiling analysis of the 3035 NSCLC-BMs found that the most frequent genomic alterations (GAs) were in the TP53, KRAS, CDKN2A, STK11, CDKN2B, EGFR, NKX2-1, RB1, MYC, and KEAP1 genes. In the NSCLC-BM cohort, there were significantly higher rates of several targetable GAs compared with pNSCLC, including ALK fusions, KRAS G12C mutations, and MET amplifications; and decreased frequency of MET exon14 skipping mutations (all P &amp;lt; .05). In the subset of NSCLC-BM (n = 1063) where concurrent PD-L1 immunohistochemistry (IHC) was performed, 54.7% of the patients with NSCLC-BM were eligible for pembrolizumab based on PD-L1 IHC (TPS \u2265 1), and 56.9% were eligible for pembrolizumab based on TMB-High status. In addition, in a series 67 paired pNSCLC and NSCLC-BM samples, 85.1% (57\/67) had at least one additional GA discovered in the NSCLC-BM sample when compared with the pNSCLC sample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Herein, we defined the clinicopathologic, genomic, and biomarker landscape of a large cohort of patients with NSCLC-BM which can help inform study design of future clinical studies for patients with NSCLC with BM. In certain clinical situations, metastatic NSCLC brain tissue or cerebral spinal fluid specimens may be needed to fully optimize personalized treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac094","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T15:15:34Z","timestamp":1650554134000},"page":"839-848","source":"Crossref","is-referenced-by-count":42,"title":["Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-5168","authenticated-orcid":false,"given":"Richard S P","family":"Huang","sequence":"first","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Harries","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Decker","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C","family":"Hiemenz","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthikeyan","family":"Murugesan","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Creeden","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Tolba","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura P","family":"Stabile","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, University of Pittsburgh , Pittsburgh, PA , USA"},{"name":"Department of Pharmacology & Chemical Biology, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti H","family":"Ramkissoon","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"},{"name":"Wake Forest Comprehensive Cancer Center, and Department of Pathology, Wake Forest School of Medicine , Winston-Salem, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F","family":"Burns","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Inc., Cambridge, MA , USA"},{"name":"Department of Pathology, State University of New York (SUNY) Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,22]]},"reference":[{"key":"2022100119180882900_CIT0001","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3747\/co.20.1481","article-title":"Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases","volume":"20","author":"Ali","year":"2013","journal-title":"Curr Oncol"},{"key":"2022100119180882900_CIT0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis","volume":"34","author":"Johung","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022100119180882900_CIT0003","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(15)00013-3","article-title":"Targeting brain metastases in ALK-rearranged non-small-cell lung cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022100119180882900_CIT0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","article-title":"Egfr mutation and brain metastasis in pulmonary adenocarcinomas","volume":"9","author":"Shin","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2022100119180882900_CIT0005","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1097\/JTO.0000000000000029","article-title":"The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer","volume":"8","author":"Gainor","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2022100119180882900_CIT0006","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fonc.2018.00414","article-title":"Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease","volume":"8","author":"Kamath","year":"2018","journal-title":"Front Oncol"},{"key":"2022100119180882900_CIT0007","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022100119180882900_CIT0008","author":"FDA."},{"key":"2022100119180882900_CIT0009","volume-title":"NCCN clinical practice guidelines in oncology, non-small cell lung cancer. Version 4.2021 March 3, 2021","author":"NCCN.","year":"2021"},{"key":"2022100119180882900_CIT0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1208\/s12248-020-00514-4","article-title":"Identification and utilization of biomarkers to predict response to immune checkpoint inhibitors","volume":"22","author":"Gjoerup","year":"2020","journal-title":"AAPS J"},{"key":"2022100119180882900_CIT0011","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41379-020-00664-y","article-title":"A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"},{"key":"2022100119180882900_CIT0012","volume-title":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors.","author":"FDA.","year":"2020"},{"key":"2022100119180882900_CIT0013","volume-title":"FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS \u22651%)","author":"FDA."},{"key":"2022100119180882900_CIT0014","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"2022100119180882900_CIT0015","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022100119180882900_CIT0016","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"Stk11\/lkb1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"2022100119180882900_CIT0017","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","article-title":"Keap1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","volume":"31","author":"Marinelli","year":"2020","journal-title":"Ann Oncol"},{"key":"2022100119180882900_CIT0018","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","article-title":"Apobec3b and apobec mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"2022100119180882900_CIT0019","doi-asserted-by":"crossref","first-page":"1550341","DOI":"10.1080\/2162402X.2018.1550341","article-title":"Apobec-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy","volume":"8","author":"Boichard","year":"2019","journal-title":"Oncoimmunology"},{"key":"2022100119180882900_CIT0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/JOP.19.00357","article-title":"Management of brain metastases in non-small-cell lung cancer","volume":"15","author":"Ernani","year":"2019","journal-title":"J Oncol Pract"},{"key":"2022100119180882900_CIT0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2022100119180882900_CIT0022","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-na\u00efve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the Alex study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"2022100119180882900_CIT0023","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ascend-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022100119180882900_CIT0024","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage iv ros1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2022100119180882900_CIT0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022100119180882900_CIT0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2022100119180882900_CIT0027","volume-title":"FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication","author":"FDA."},{"key":"2022100119180882900_CIT0028","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"key":"2022100119180882900_CIT0029","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"2022100119180882900_CIT0030","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1158\/1538-7445.AM2019-1599","article-title":"Abstract 1599: determining patient ancestry based on targeted tumor comprehensive genomic profiling","volume":"79","author":"Newberg","year":"2019","journal-title":"Cancer Res"},{"key":"2022100119180882900_CIT0031","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2020.04.012","article-title":"Comprehensive analysis of genetic ancestry and its molecular correlates in cancer","volume":"37","author":"Carrot-Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"2022100119180882900_CIT0032","volume-title":"PD-L1 IHC 22c3 pharmdx package insert","author":"DAKO","year":"2020"},{"key":"2022100119180882900_CIT0033","volume-title":"PD-L1 IHC 22c3 pharmdx interpretation manual \u2013 NSCLC.","author":"DAKO."},{"key":"2022100119180882900_CIT0034","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/sim.6082","article-title":"Multiple hypothesis testing in genomics","volume":"33","author":"Goeman","year":"2014","journal-title":"Stat Med"},{"key":"2022100119180882900_CIT0035","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for pik3ca-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"2022100119180882900_CIT0036","doi-asserted-by":"crossref","first-page":"544680","DOI":"10.3389\/fneur.2020.544680","article-title":"Genomic profiling of circulating tumor DNA from cerebrospinal fluid to guide clinical decision making for patients with primary and metastatic brain tumors","volume":"11","author":"Ramkissoon","year":"2020","journal-title":"Front Neurol"},{"key":"2022100119180882900_CIT0037","doi-asserted-by":"crossref","first-page":"592997","DOI":"10.3389\/pore.2021.592997","article-title":"Landscape of biomarkers in non-small cell lung cancer using comprehensive genomic profiling and PD-L1 immunohistochemistry","volume":"27","author":"Huang","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"2022100119180882900_CIT0038","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2020-0449","article-title":"Biomarkers in breast cancer: an integrated analysis of comprehensive genomic profiling and PD-L1 immunohistochemistry biomarkers in 312 patients with breast cancer","volume":"25","author":"Huang","year":"2020","journal-title":"Oncologist"},{"key":"2022100119180882900_CIT0039","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/onco.13753","article-title":"Clinicopathologic and genomic characterization of PD-L1 positive urothelial carcinomas","volume":"26","author":"Huang","year":"2021","journal-title":"Oncologist"},{"key":"2022100119180882900_CIT0040","doi-asserted-by":"crossref","first-page":"e002230","DOI":"10.1136\/jitc-2020-002230","article-title":"Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer","volume":"9","author":"Moutafi","year":"2021","journal-title":"J ImmunoTher Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/839\/46285000\/oyac094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/839\/46285000\/oyac094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T15:20:03Z","timestamp":1664637603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/10\/839\/6590419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,22]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5,22]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac094","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,5,22]]}}}